Clinical trial
Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or…
NCT00293111 · Cephalon, Industry · Terminated
Key facts
| NCT number | NCT00293111 |
|---|---|
| Title | Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) |
| Official title | An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) |
| Lead sponsor | Cephalon, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | SDX-101 (R-Etodolac) |
| Enrollment | 30 |
| Start date | Feb 1, 2002 |
| Primary completion | Oct 1, 2003 |
| First posted | Feb 17, 2006 |
| Last update posted | May 12, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: